Sanofi (NASDAQ:SNY) (OTCPK: SNYNF) said Monday that an upgraded version of the COVID-19 vaccine the company is developing with GSK (GSK) works better than Pfizer (PFE) / BioNTech (BNTX) vaccine as a booster shot against the Omicron variant.
The 247-subject study was designed to evaluate the efficacy of the next-generation recombinant and recombinant vaccine candidates Sanofi-GSK and the third dose of Pfizer (PFE) / BioNTech (BNTX) vaccine in individuals who initially received two doses of the mRNA-based vaccine.
All three vaccines produced neutralizing antibodies against the Omicron variant BA.1. However, the Sanofi-GSK next-generation candidate produced the highest response, according to data published as a pre-print prior to peer review.
Another late-stage trial involved 1,500 people of those who had previously received an mRNA vaccine, such as the one from Pfizer (PFE) / BioNTech (BNTX) and Moderna (mRNA), indicating that the new vaccine candidate led to a significant increase in antibody levels against some of the variants of interest.
According to initial data, there was a 40-fold increase in antibody titers against variant BA.1 and the new vaccine version doubled the number of neutralizing antibodies against Omicron BA.1 and BA. 2 compared with the original vaccine candidate.
Both studies showed that the experimental vaccine was well tolerated with favorable safety profile. However, the 1,500 . group the subjects in the second test are shown less than 4% of tertiary reactions, according to Sanofi (SNY), is temporary and not serious.
Read about the prospect of a Sanofi-GSK vaccine against mRNA vaccines are widely used.